Beyond location: How technological advances in diagnostics are redefining cancer care

MANY FACTORS CAN impact the life expectancy of a patient with cancer including access to screening, accessible health care providers, socioeconomic status, race, ethnicity, and even a patient’s zip code. These social factors can be the critical determinants between effective, life saving care or care that arrived too little, too late. Labcorp is working to address equity and access for all patients needing cancer care. This global life sciences company is democratizing oncology care through new technologies, improved access to diagnostic testing, and more inclusive clinical trials.

Understanding the Bhas 42 cell transformation assay: A first step in detecting carcinogenesis

Responding to a need to provide testing solutions that may help reduce timelines, costs and complexities for our drug development partners, Labcorp is pleased to now offer the Bhas 42 cell transformation assay (CTA) in support of preclinical toxicology studies.